182,992 Shares in Harvard Bioscience, Inc. $HBIO Acquired by Meros Investment Management LP

Meros Investment Management LP purchased a new stake in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) in the second quarter, HoldingsChannel reports. The institutional investor purchased 182,992 shares of the medical instruments supplier’s stock, valued at approximately $1,125,401,000.

Several other hedge funds also recently modified their holdings of the company. Corsair Capital Management L.P. grew its position in Harvard Bioscience by 1,008.7% in the fourth quarter. Corsair Capital Management L.P. now owns 1,108,692 shares of the medical instruments supplier’s stock worth $741,000 after buying an additional 1,008,692 shares during the last quarter. Nano Cap New Millennium Growth Fund L P acquired a new stake in shares of Harvard Bioscience during the 4th quarter valued at $401,000. Two Sigma Investments LP boosted its stake in shares of Harvard Bioscience by 139.7% during the 3rd quarter. Two Sigma Investments LP now owns 474,157 shares of the medical instruments supplier’s stock worth $208,000 after acquiring an additional 276,372 shares in the last quarter. Strs Ohio acquired a new position in shares of Harvard Bioscience in the 1st quarter worth $117,000. Finally, Essex Investment Management Co. LLC acquired a new position in shares of Harvard Bioscience in the 4th quarter worth $124,000. 80.87% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Weiss Ratings downgraded shares of Harvard Bioscience from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, August 14th. Benchmark upped their target price on Harvard Bioscience from $6.00 to $7.50 and gave the company a “speculative buy” rating in a report on Wednesday, August 12th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.75.

Harvard Bioscience Stock Up 0.4%

Shares of HBIO stock opened at $7.58 on Wednesday. The stock’s 50 day simple moving average is $6.31 and its 200 day simple moving average is $5.92. Harvard Bioscience, Inc. has a twelve month low of $3.75 and a twelve month high of $9.40. The company has a debt-to-equity ratio of 4.94, a quick ratio of 0.98 and a current ratio of 1.87. The company has a market capitalization of $34.49 million, a price-to-earnings ratio of -3.28 and a beta of 1.49.

Harvard Bioscience (NASDAQ:HBIO) last announced its earnings results on Tuesday, August 11th. The medical instruments supplier reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.07. Harvard Bioscience had a negative return on equity of 33.13% and a negative net margin of 11.86%.The firm had revenue of $22.73 million during the quarter, compared to analysts’ expectations of $21.45 million.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.